The home page is here. Agenda Day 1 is here, Agenda Day 2 is here.
Speakers include Scott Gottlieb, head of the agency, and Janet Woodcock, head of CDER.
Topics include updates on post market studies and surveillance, FDA's use of patient reported outcomes, precision medicine, accelerated approval, expanded access issues (eg right to try), value and price transparency, Medicaid update, biosimilars in US versus globally, and rare diseases and pandemics.
